Jonathan Tobin’s Post

At SciTech, we are pioneering a new approach to cancer treatment with our investigational drug ST-001. By combining fenretinide with phospholipids in our innovative nanoparticalized delivery platform (SDP), we are enhancing the efficacy of cancer therapy in groundbreaking ways. Why This Matters: Targeted Delivery: ST-001 is designed to effectively transport fenretinide directly to cancer cells, optimizing its potential to kill cancerous cells while minimizing side effects. Enhanced Bioavailability: Our unique SDP overcomes traditional drug delivery challenges, ensuring that a higher concentration of the drug reaches its target. Multiple Mechanisms of Action: Fenretinide is known for its multiple anti-cancer mechanisms, providing a powerful therapeutic option for patients battling various forms of cancer. With ST-001, we are not just treating cancer; we are revolutionizing the way it is fought. Join us on this journey toward innovative cancer solutions! https://scitechsdp.com/ #scitech #research #patented #scitechSDP #scitechdevelopment #oncology #nanofenretinide #fenretinide #lymphoma #nonhodgkin #drugdelivery #ST001

✨ Excited to Share My Latest Research! ✨ I'm thrilled to announce that my recent article, "PNU-74654 Enhanced the Antiproliferative Activity of Gemcitabine by Targeting the Wnt/β-Catenin Pathway in Pancreatic Cancer," is now published! This study explores the potential of PNU-74654 to boost the effectiveness of gemcitabine, a common chemotherapy drug, by targeting the Wnt/β-catenin pathway, a key player in cancer cell growth and survival. Our findings shed light on new avenues for potentially improving treatment strategies for pancreatic cancer, a highly challenging and aggressive form of cancer. 🔍 Highlights: PNU-74654's role in amplifying gemcitabine’s antiproliferative effects. Mechanistic insights into Wnt/β-catenin pathway modulation in pancreatic cancer cells. Potential implications for enhancing treatment responses in patients. I am incredibly grateful to my co-authors, mentors, and everyone who supported this research journey. I hope our findings will contribute to the ongoing efforts in developing more effective cancer therapies. Feel free to reach out if you’d like to discuss this further or share your thoughts! #CancerResearch #Oncology #PancreaticCancer #WntPathway #Gemcitabine #ScientificResearch #InnovationInHealthcare

🌐 Exciting development in cancer treatment! Zymeworks Inc. has dosed the first patient in their Phase 1 clinical trial of ZW191, an innovative antibody-drug conjugate designed to target folate receptor-⍺ (FR⍺) in advanced cancers like ovarian, endometrial, and non-small cell lung cancers. FR⍺, highly expressed in certain tumors but limited in healthy tissues, acts as an ideal target for ZW191, enabling precise delivery of a cytotoxic payload directly to cancer cells. This targeted approach promises not only improved efficacy but also reduced side effects, offering new hope for patients with difficult-to-treat cancers. This global study is a significant milestone for Zymeworks' pipeline and a promising step forward in pioneering effective therapies in oncology. Looking forward to seeing how this will positively impact patients and the future of cancer care! #Oncology #CancerResearch #Biotech #Innovation #ClinicalTrials #ZW191 #CancerTreatment

Lamassu BioTech, a cutting-edge biotech company dedicated to innovative cancer therapies, has been awarded a grant from the The National Institutes of Health and National Cancer Institute (NCI) for the development of their groundbreaking treatment for p53 wild-type sarcomas. The project focuses on advancing SA53, a novel therapeutic that targets p53 wild-type sarcomas, malignant tumors of connective or non-epithelial tissue. SA53 has demonstrated remarkable potency, efficacy and safety in preclinical models, positioning it for an Investigational New Drug (IND) submission. This innovative approach offers promising prospects for addressing chemo-resistant cancer and presents a significant pathway for advancing cancer care. Read more here: https://lnkd.in/dWCkg6Ya

Data from SWOG Cancer Research Network 1216 trial in mHSPC - Neeraj Agarwal, MD, FASCO https://lnkd.in/gmH7j7VR #SWOGtrial #mHSPC #cancerresearch #PSAlevel #biomarkers #clinicaltrials #prognosticmarkers #canceroutcome

The global oncology community gathered at ASCO 2024 from May 31st to June 4th, 2024. The theme of the meeting was The Art and Science of Cancer Care: From Comfort to Cure. Oncology professionals from across the globe were united and forged collaborations to change the landscape of cancer care. Our team at THB brings to you the important highlights of Breast Cancer- Key Findings on Approved Therapies. >> Eribulin could be considered a viable alternative treatment option to taxane-based therapies. >> T-DXd has demonstrated promising efficacy in HER2 low and HER2 ultra-low advanced breast cancer patients who have previously been treated with endocrine therapy >> Abemaciclib + Fulvestrant shows promising clinical efficacy in CDKi Pretreated HER2-Advanced Breast Cancer These findings presented at the conference highlight the crucial need for ongoing research and advancements. They also offer significant treatment options and a ray of hope for Indian patients who require medical attention. Author- Arun Nayak | Reviewer- Lavina Yadav #ASCO2024 #BreastCancer #ClinicalTrials #OncologyInnovations

Promising findings in ASCO 2024 These results have the potential to alter current breast cancer treatment patterns in real-world practice. #ASCO2024

#ARTEMISPC #MRD #clinicaltrial in #patients w/ resectable & unresectable #pancreaticcancer Invitae #NationalCancerCenterHospitalEast #TrialsinProgress #GI24 @ American Society of Clinical Oncology (ASCO) https://lnkd.in/gVW5BFh9 https://lnkd.in/gJNSmdWS Video Journal of Oncology (VJOncology) Pancreatic Cancer Action Network Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC)

NEW from #ASCOGI 2024 | ARTEMIS-PC: personalized panel for circulating tumor DNA in #pancreaticcancer 🇺🇸 🎥 Ed Esplin, MD, PhD, Invitae, discusses the urgent need for innovative #diagnostic and #therapeutic approaches in #pancreaticcancer (PC) Current challenges include the low sensitivity of #circulatingtumorDNA (#ctDNA) assays in PC due to its high stromal and low cellular features The Invitae Personalized Cancer Monitoring™ test, a novel and highly sensitive #tumor-informed #minimalresidualdisease (#MRD) detection assay, is introduced. The ARTEMIS-PC study (NCT06043921), a prospective observational trial in Japan, aims to assess the clinical utility of this assay in 150 patients with #resectable and #unresectable PC 🌟 Primary and secondary endpoints include the success rate of creating personalized panels, concordance of #KRASmutations, and #ctDNA positivity rates at various stages. The study commenced enrollment in December 2022💡 Learn more 👉 https://lnkd.in/erbH38SF #VJOncology American Society of Clinical Oncology (ASCO)

🚀 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐦𝐞𝐧𝐭𝐬 𝐢𝐧 𝐓𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐂𝐚𝐧𝐜𝐞𝐫 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 🎗️ Targeted therapies are revolutionizing cancer treatment, focusing on specific mechanisms to enhance efficacy. Key drug targets include: 𝐄𝐆𝐅𝐑, 𝐀𝐋𝐊, 𝐏𝐃-1/𝐏𝐃-𝐋1: Vital for lung cancer therapies. 𝐇𝐄𝐑2: Central to breast cancer treatment. 𝐕𝐄𝐆𝐅-𝐀: Targeted in ovarian and colorectal cancers. 𝐁𝐂𝐑-𝐀𝐁𝐋 and 𝐂𝐃20: Important for leukemia therapies. 𝐀𝐧𝐝𝐫𝐨𝐠𝐞𝐧 𝐑𝐞𝐜𝐞𝐩𝐭𝐨𝐫: Key in prostate cancer. Sino Biological, Inc. is committed to supporting cancer research with a diverse range of high-quality products. A detailed overview of our offering can be found here: https://lnkd.in/edUMqu4w Let’s drive innovation in cancer treatment together! 💪 As together, we can achieve more 🤝 #CancerResearch #TargetedTherapy #Oncology 𝘈𝘐 𝘎𝘦𝘯𝘦𝘳𝘢𝘵𝘦𝘥 𝘐𝘮𝘢𝘨𝘦